SBIR Phase I: Dense Nanolipid Fluids (DNLFs) for Delivery of Drugs with Poor Bioavailability: Synthesis, Manufacture, and Drug Properties

SBIR 第一阶段：用于递送生物利用度较差的药物的致密纳米脂质流体 (DNLF)：合成、制造和药物特性

• 批准号: 2212222
• 负责人: Eric Morrison
• 金额: $ 25.6万
• 依托单位: SUPERIOR NANO LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-15 至 2023-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2212222&HistoricalAwards=false
• 关键词: SBIR; Phase; Dense; Nanolipid; Fluids

The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to care for patients suffering from diseases including diabetes, multiple Sclerosis (MS), acquired immunodeficiency syndrome (AIDS), and cancer using nano dosage forms of drug molecules. Making drugs nano-sized helps them be absorbed and move to parts of the body where needed. The ability to manufacture nanosized drugs comes from the discovery that drug sizes may be decreased with a twin screw extruder, a type of machine usually used to produce bulk products such as plastic pipes, garbage bags, snack foods, cereal, and pasta. Before the discovery of the twin screw extruder, drug nanoparticles were only made in thimbleful quantities and were prohibitively expensive. This NSF SBIR Phase I project seeks to tap the potential of nano-sized drug forms by allowing them to be made economically and getting them into the hands of medical researchers. This Small Business Innovation Research (SBIR) Phase I project seeks to provide new knowledge related to surfactant-lipid-water systems and drug delivery nanoparticles. Although there has been much research focused on increasing the body’s absorption of drugs using lipid nanoparticles, translation to the clinic has been limited because nanoparticles cannot be produced with sufficient reproducibility, quality, or in sufficient quantities, making them prohibitively expensive. This SBIR project seeks to solve these problems by using twin-screw extrusion, a process typically used for bulk manufacturing of commodity goods such as plastic pipes, garbage bags, snack foods and pasta. The twin screw extruder process is based on the transient formation of rupturable surfactant-lipid-water mesophases during transit through the extruder barrel. To be successful at the twin screw extrusion of drug nano dosage forms, new scientific knowledge must be created to advance conceptualization of surfactant-lipid-water systems from time invariant equilibrium structures to highly time dependent dynamic non-equilibrium processes.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业创新研究 (SBIR) 第一阶段项目的更广泛影响/商业潜力是使用药物纳米剂型来护理患有糖尿病、多发性硬化症 (MS)、获得性免疫缺陷综合症 (艾滋病) 和癌症等疾病的患者将药物制成纳米尺寸有助于它们被吸收并移动到需要的身体部位。制造纳米药物的能力来自于发现双螺杆挤出机可以减小药物尺寸，双螺杆挤出机是一种通常用于制造纳米尺寸药物的机器。生产大宗产品，例如在双螺杆挤出机发明之前，药物纳米颗粒的生产量非常小，而且价格极其昂贵。 NSF SBIR 第一阶段项目旨在挖掘纳米颗粒的潜力。该小型企业创新研究 (SBIR) 第一阶段项目旨在提供与表面活性剂-脂质-水系统和药物输送相关的新知识。尽管已经有很多研究集中在使用脂质纳米颗粒来增加人体对药物的吸收，但由于纳米颗粒的生产无法具有足够的可重复性、质量或足够的数量，因此其临床应用受到限制，这使得这种 SBIR 成本过高。该项目旨在通过使用双螺杆挤出来解决这些问题，双螺杆挤出机是一种通常用于批量生产塑料管、垃圾袋、休闲食品和面食等商品的工艺。在通过挤出机机筒的过程中短暂形成可破裂的表面活性剂-脂质-水中间相。为了成功地进行药物纳米剂型的双螺杆挤出，必须创造新的科学知识来推进表面活性剂-脂质-水系统的时不变概念化。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响审查标准进行评估，被认为值得支持。